Author

Dervla T. Isaac

Ribon Therapeutics (United States)ORCID 0009-0000-6165-345XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Adam F. L. HurlstoneiD· 1 shared Chun Wai WongiD· 1 shared I‐Hsuan LiniD· 1 shared Kieran N. SeftoniD· 1 shared Mario NiepeliD· 1 shared Rotem LeshemiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam F. L. HurlstoneORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyJournal for ImmunoTherapy of CancerPeer-reviewedJan 1, 2025

Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarisation in Relapsed Melanoma

Rotem Leshem, Kieran N. Sefton, Chun Wai Wong…·Adam F. L. Hurlstone

This paper shows that combining PARP14 inhibition with PD-1 blockade enhances immune responses in melanoma by promoting T cell quiescence and modulating macrophage polarization.

10 citationstop 5%

mousebulk RNA-seq

𝕏 PostBluesky